xFgkHcoP |
| MRjlnsAOcniJlHUhfSo [2019-12-22] |
| Where are you calling from? http://pron.in.net/ pron hub The ASTERIA I study showed that patients treated with omalizumab 300 mg dose responded as early as Week 1, compared to Week 4 in the placebo group. By Week 12, all three omalizumab doses of 300 mg, 150 mg and 75 mg were significantly superior to placebo in improving patients' weekly Itch Severity Score or ISS, which was the primary endpoint of the study. This benefit was maintained throughout active treatment.
|
|
|
